Ace Your NRNP 6675 Final Exam: Updated
2025/2026 PMHNP Practice Questions &
Answers
Description:
Get fully prepared with the most accurate and up-to-date collection of NRNP 6675 exam
questions—meticulously reviewed and aligned with 2025/2026 guidelines. This resource
includes detailed explanations and covers key PMHNP topics like psychopharmacology,
diagnosis, ethics, and treatment planning. Whether you're reviewing for certification or
deepening your clinical knowledge, this tool builds confidence and mastery.
Master your exam—download now and pass with precision!
, NRNP 6675 Final Exam 2025/2026: PMHNP Questions & Answers
1. Which of the following are risk factors for neuroleptic malignant syndrome? (Select all that
apply)
A. Rapid dose escalation
B. Parenteral route of administration
C. Use of high-potency first-generation (typical) antipsychotics
D. Dehydration and agitation
Answer: A, B, C, D
Explanation: NMS risk is increased by rapid dose escalation, intramuscular administration, use
of high-potency typical antipsychotics (e.g., haloperidol), and patient factors like dehydration,
agitation, and physical exhaustion.
2. The discrepancy between a person's assigned sex at birth and their gender identity is known
as:
A. Gender Dysphoria
B. Gender Discordance
C. Transvestic Disorder
D. Sexual Dysmorphia
Answer: A. Gender Dysphoria
Explanation: Gender Dysphoria is the clinically significant distress caused by a discrepancy
between one’s experienced/expressed gender and assigned gender, as defined in the DSM-5-TR.
"Gender Discordance" is not a standard diagnostic term.
3. Antipsychotic medication provides D2 blockade in the mesocortical pathway, causing which
of the following effects?
A. Reduces negative symptoms
B. Increases extrapyramidal symptoms (EPS)
C. Causes hyperprolactinemia
D. Reduces positive symptoms
, Answer: B. Increases extrapyramidal symptoms (EPS)
Explanation: While D2 blockade in the mesolimbic pathway reduces positive symptoms,
blockade in the mesocortical pathway (involved in cognition and emotion) is associated with
worsening negative symptoms and an increased risk of EPS, not their reduction.
4. Phencyclidine (PCP) and ketamine exert their unique behavioral effects by blocking which of
the following receptors?
A. GABA receptors
B. Serotonin receptors
C. Dopamine receptors
D. NMDA glutamate receptors
Answer: D. NMDA glutamate receptors
Explanation: PCP and ketamine are noncompetitive antagonists of the NMDA receptor, leading
to dissociative symptoms, psychosis, and cognitive disturbances.
5. The diagnosis used to describe a syndrome characterized by specific signs and symptoms
resulting from recent ingestion or exposure to a substance is known as:
A. Substance Use Disorder
B. Substance Intoxication
C. Substance Withdrawal
D. Substance-Induced Disorder
Answer: B. Substance Intoxication
Explanation: Substance Intoxication is the diagnosis for a reversible substance-specific
syndrome due to recent ingestion. Substance Use Disorder is a broader pattern of problematic
use, and Withdrawal is a syndrome due to cessation or reduction of use.
6. Abnormal involuntary movements in a rhythmic pattern affecting the face, mouth, tongue, and
jaw is known as:
A. Akathisia
B. Dystonia
2025/2026 PMHNP Practice Questions &
Answers
Description:
Get fully prepared with the most accurate and up-to-date collection of NRNP 6675 exam
questions—meticulously reviewed and aligned with 2025/2026 guidelines. This resource
includes detailed explanations and covers key PMHNP topics like psychopharmacology,
diagnosis, ethics, and treatment planning. Whether you're reviewing for certification or
deepening your clinical knowledge, this tool builds confidence and mastery.
Master your exam—download now and pass with precision!
, NRNP 6675 Final Exam 2025/2026: PMHNP Questions & Answers
1. Which of the following are risk factors for neuroleptic malignant syndrome? (Select all that
apply)
A. Rapid dose escalation
B. Parenteral route of administration
C. Use of high-potency first-generation (typical) antipsychotics
D. Dehydration and agitation
Answer: A, B, C, D
Explanation: NMS risk is increased by rapid dose escalation, intramuscular administration, use
of high-potency typical antipsychotics (e.g., haloperidol), and patient factors like dehydration,
agitation, and physical exhaustion.
2. The discrepancy between a person's assigned sex at birth and their gender identity is known
as:
A. Gender Dysphoria
B. Gender Discordance
C. Transvestic Disorder
D. Sexual Dysmorphia
Answer: A. Gender Dysphoria
Explanation: Gender Dysphoria is the clinically significant distress caused by a discrepancy
between one’s experienced/expressed gender and assigned gender, as defined in the DSM-5-TR.
"Gender Discordance" is not a standard diagnostic term.
3. Antipsychotic medication provides D2 blockade in the mesocortical pathway, causing which
of the following effects?
A. Reduces negative symptoms
B. Increases extrapyramidal symptoms (EPS)
C. Causes hyperprolactinemia
D. Reduces positive symptoms
, Answer: B. Increases extrapyramidal symptoms (EPS)
Explanation: While D2 blockade in the mesolimbic pathway reduces positive symptoms,
blockade in the mesocortical pathway (involved in cognition and emotion) is associated with
worsening negative symptoms and an increased risk of EPS, not their reduction.
4. Phencyclidine (PCP) and ketamine exert their unique behavioral effects by blocking which of
the following receptors?
A. GABA receptors
B. Serotonin receptors
C. Dopamine receptors
D. NMDA glutamate receptors
Answer: D. NMDA glutamate receptors
Explanation: PCP and ketamine are noncompetitive antagonists of the NMDA receptor, leading
to dissociative symptoms, psychosis, and cognitive disturbances.
5. The diagnosis used to describe a syndrome characterized by specific signs and symptoms
resulting from recent ingestion or exposure to a substance is known as:
A. Substance Use Disorder
B. Substance Intoxication
C. Substance Withdrawal
D. Substance-Induced Disorder
Answer: B. Substance Intoxication
Explanation: Substance Intoxication is the diagnosis for a reversible substance-specific
syndrome due to recent ingestion. Substance Use Disorder is a broader pattern of problematic
use, and Withdrawal is a syndrome due to cessation or reduction of use.
6. Abnormal involuntary movements in a rhythmic pattern affecting the face, mouth, tongue, and
jaw is known as:
A. Akathisia
B. Dystonia
